Breaking Down Aspira Women's Health Inc. (AWH) Financial Health: Key Insights for Investors

Are you keeping a close watch on the financial health of Aspira Women's Health Inc. (AWH) and what insights can investors glean from their performance? Despite a challenging market environment, Aspira Women's Health reported flat product revenue at $9.2 million for the year ended December 31, 2024, the number of OvaSuite tests performed increased by 1.3% to approximately 24,305. Want to know how Aspira Women's Health managed to improve its gross profit margin to 59.7% and decrease operating expenses by 10%? Read on to discover key financial highlights, strategic initiatives, and expert analyses that could shape your investment decisions.

Aspira Women's Health Inc. (AWH) Revenue Analysis

Aspira Women's Health Inc. (AWH) operates primarily in the women's health sector, focusing on diagnostic testing and services. A revenue analysis provides critical insights into the company's financial stability and growth potential. Let's explore the key components of AWH's revenue streams.

Aspira Women's Health focuses on innovative gynecologic health, offering a suite of tests and bio-analytical solutions that help physicians assess risk, optimize patient management and improve lives. The company's key revenue sources include:

• Diagnostic Testing Services: Revenue is generated from proprietary diagnostic tests like OvaSuite, which includes OVA1 Plus, and other related tests used in the assessment of ovarian cancer risk.
• Bio-Analytical Services: Income derived from bio-analytical solutions and other services provided to healthcare providers.

Analyzing Aspira Women's Health's year-over-year revenue growth rate provides a clear picture of its financial trajectory. Examining historical trends in revenue growth helps investors understand the company’s ability to expand its market presence and increase sales. Here’s what we can infer regarding revenue trends based on available information:

Aspira Women's Health reported revenue of $39.1 million for the year ended December 31, 2023, representing an increase of $7.9 million, or 25.3%, compared to $31.2 million for the year ended December 31, 2022. This increase was primarily driven by a 28.1% increase in test volume. For the three months ended December 31, 2023, the company reported revenue of $10.4 million, a 10.3% increase compared to $9.4 million for the three months ended December 31, 2022.

The growth can be attributed to several factors, including increased market penetration, higher demand for diagnostic services, and successful commercial strategies. Monitoring these rates helps in forecasting future performance and evaluating the effectiveness of AWH’s business strategies.

Understanding the contribution of different business segments to Aspira Women's Health's overall revenue is crucial for assessing the company's financial health. Here’s a breakdown:

• OVA1 Plus: This test is a significant revenue driver, aiding in the assessment of ovarian cancer risk.
• Other Diagnostic Tests: Include a range of diagnostic solutions, each contributing differently to the total revenue.
• Bio-Analytical and Other Services: These services provide additional revenue streams, supporting the company’s overall financial performance.

Here is a table summarizing revenue contributions by source, based on the latest available data:

Analyzing changes in revenue streams is essential for understanding the evolving dynamics of Aspira Women's Health's business. Significant shifts in revenue sources can indicate strategic realignments, market changes, or the impact of new products and services. Key factors to consider include:

• Market Expansion: Entering new geographic regions or expanding the customer base can lead to increased revenue from specific tests or services.
• Regulatory Changes: Changes in healthcare regulations or reimbursement policies can impact the demand for certain diagnostic tests.
• Technological Advancements: Introduction of new, innovative tests or improvements to existing ones can drive revenue growth.

For instance, the growth in test volume by 28.1% in 2023 indicates a strong market uptake of Aspira Women's Health's diagnostic solutions. Monitoring these changes helps investors stay informed about the company's strategic direction and potential growth areas.

Keep exploring more about Aspira Women's Health Inc. (AWH): Exploring Aspira Women's Health Inc. (AWH) Investor Profile: Who’s Buying and Why?

Aspira Women's Health Inc. (AWH) Profitability Metrics

Analyzing Aspira Women's Health Inc.'s profitability involves examining several key metrics that provide insights into the company's financial health and operational efficiency. These metrics include gross profit, operating profit, and net profit margins, which are crucial for investors to understand the company's ability to generate profits from its revenue.

Here's a detailed look into these metrics:

• Gross Profit: This is the revenue a company has left after deducting the cost of goods sold (COGS). It indicates how efficiently a company manages its production costs.
• Operating Profit: This profit is earned from business operations after deducting operating expenses such as wages, depreciation, and the cost of goods sold. It reflects the company's efficiency in managing its operational costs.
• Net Profit: This is the profit remaining after all expenses, including taxes and interest, have been deducted from total revenue. Net profit represents the actual profit the company earns, which can be reinvested into the business or distributed to its owners.

To provide a clear picture of Aspira Women's Health Inc.'s financial performance, here's a table summarizing key profitability figures:

Aspira Women's Health Inc. has shown consistent improvement in its gross profit and gross margin over the past three years. In 2024, the gross profit reached $34.4 million, with a gross margin of 53.9%. Despite these gains, the company still faces challenges in achieving overall profitability, as evidenced by the operating and net losses. However, there has been a notable reduction in both operating and net losses from 2022 to 2024, indicating positive strides in financial management and cost control.

When comparing Aspira Women's Health Inc.'s profitability ratios with industry averages, it's essential to consider the specific sector and competitive landscape. Industry benchmarks can provide insights into whether the company's performance is on par with its peers or if there are areas needing improvement. For instance, if the industry average for gross margin is significantly higher, it may suggest that Aspira Women's Health Inc. needs to optimize its cost of goods sold or pricing strategies.

Analysis of operational efficiency is crucial for understanding how well Aspira Women's Health Inc. manages its resources. Effective cost management and favorable gross margin trends are indicators of strong operational performance. The company's ability to reduce its operating and net losses year over year suggests improvements in managing operational expenses and enhancing overall efficiency.

Learn more about the investors behind Aspira Women's Health Inc.: Exploring Aspira Women's Health Inc. (AWH) Investor Profile: Who’s Buying and Why?

Aspira Women's Health Inc. (AWH) Debt vs. Equity Structure

Understanding how Aspira Women's Health Inc. (AWH) finances its operations and growth is crucial for investors. This involves looking at the company's debt levels, its debt-to-equity ratio, and how it manages its financing strategies.

As of the fiscal year 2024, Aspira Women's Health Inc. (AWH) showcases the following financial data:

• Cash and cash equivalents: $25.8 million
• Total debt: $29.1 million

Aspira Women's Health Inc. (AWH) relies on a mix of debt and equity to fund its activities. Here’s a closer look at these components:

Overview of Debt Levels:

As of fiscal year 2024, Aspira Women's Health Inc. (AWH) has a total debt of $29.1 million. This includes both short-term and long-term debt obligations. Monitoring these levels helps in assessing the company’s financial risk and stability.

Debt-to-Equity Ratio:

The debt-to-equity ratio is a key metric for evaluating a company's financial leverage. This ratio indicates the proportion of debt and equity a company uses to finance its assets. While the exact debt-to-equity ratio for Aspira Women's Health Inc. (AWH) as of 2024 isn't specified, we can provide context based on general financial principles. A higher ratio indicates greater financial risk, as the company relies more on debt than equity. Investors often compare this ratio to industry standards to gauge whether the company's leverage is typical for its sector.

Recent Debt and Financing Activities:

Aspira Women's Health Inc. (AWH) has been actively managing its debt through various financing activities. Here’s a snapshot:

• February 2024: Raised $5 million via the sale of Series A Preferred Stock and warrants.
• March 2024: Secured $22.5 million in additional funding through a warrant exercise agreement.
• April 2024: Completed a registered direct offering, raising $7.2 million.

These activities show Aspira Women's Health Inc. (AWH)'s proactive approach to strengthening its financial position through equity and warrant offerings.

Balancing Debt and Equity:

Aspira Women's Health Inc. (AWH) strategically balances debt and equity to optimize its capital structure. While debt can provide necessary funds for growth, it also introduces financial risk through interest payments and the need for repayment. Equity financing, on the other hand, doesn't require repayment but can dilute existing shareholders' ownership. Aspira Women's Health Inc. (AWH)'s recent financing activities, particularly the offerings of preferred stock and warrants, indicate a focus on bolstering its equity base to support its operational and strategic objectives.

For further insights into Aspira Women's Health Inc. (AWH) and its investors, check out: Exploring Aspira Women's Health Inc. (AWH) Investor Profile: Who’s Buying and Why?

Aspira Women's Health Inc. (AWH) Liquidity and Solvency

Assessing the liquidity and solvency of Aspira Women's Health Inc. (AWH) is crucial for investors to understand the company's short-term and long-term financial health. Liquidity measures AWH's ability to meet its short-term obligations, while solvency indicates its ability to meet long-term obligations.

Here's a breakdown of key liquidity and solvency indicators for Aspira Women's Health Inc. (AWH):

Assessing Aspira Women's Health Inc.'s Liquidity:

• Current and Quick Ratios: These ratios provide insights into AWH's ability to cover its short-term liabilities with its short-term assets.

For the fiscal year 2024, AWH's liquidity positions can be assessed using these metrics:

• The current ratio, calculated by dividing current assets by current liabilities, was approximately 1.4x as of December 31, 2024.
• The quick ratio, which excludes inventories from current assets to provide a more conservative measure, stood at about 1.3x for the same period.

• Analysis of Working Capital Trends: Working capital, calculated as current assets minus current liabilities, indicates the company's operational liquidity.

Reviewing the trend of AWH's working capital provides a clearer picture:

• AWH's working capital as of December 31, 2024, was approximately $14.4 million.

• Cash Flow Statements Overview: Analyzing cash flow trends from operating, investing, and financing activities is vital for assessing liquidity.

Key observations from the cash flow statement include:

• Net cash used in operating activities for the year ended December 31, 2024, was approximately $27.5 million.
• Net cash used in investing activities was about $0.2 million, primarily for equipment purchases.
• Net cash provided by financing activities totaled approximately $30.7 million, mainly from the proceeds of the term loan facility.

• Potential Liquidity Concerns or Strengths: Evaluating these metrics helps identify potential liquidity issues or strengths.

Based on the 2024 data:

• AWH's current and quick ratios suggest a reasonable ability to meet short-term obligations.
• However, the negative cash flow from operating activities indicates a need for improved operational efficiency or additional funding.
• The cash provided by financing activities was crucial in maintaining liquidity, highlighting the importance of managing debt and equity effectively.

For further insights into the company's mission, vision, and core values, you can refer to this link: Mission Statement, Vision, & Core Values of Aspira Women's Health Inc. (AWH).

Aspira Women's Health Inc. (AWH) Valuation Analysis

Determining whether Aspira Women's Health Inc. (AWH) is overvalued or undervalued requires a multifaceted approach, incorporating key financial ratios, stock performance analysis, and analyst opinions. Let's delve into the critical metrics that provide insights into AWH's valuation.

To assess whether Aspira Women's Health Inc. (AWH) is overvalued or undervalued, consider the following:

• Price-to-Earnings (P/E) Ratio: The P/E ratio, a fundamental valuation metric, is calculated by dividing a company's stock price by its earnings per share (EPS). As of the latest data, Aspira Women's Health Inc. does not have a P/E ratio because the EPS is negative.
• Price-to-Book (P/B) Ratio: The Price-to-Book ratio is calculated by dividing a company's market capitalization by its book value of equity. As of its most recent report, Aspira Women's Health Inc.'s (AWH) Price/Book ratio is 2.94.
• Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: The EV/EBITDA ratio compares a company's enterprise value to its earnings before interest, taxes, depreciation, and amortization (EBITDA). As of the latest information, Aspira Women's Health Inc. does not have an EV/EBITDA ratio because the EBITDA is negative.

Analyzing Aspira Women's Health Inc.'s stock price trends over the last 12 months provides crucial context. The stock's performance reflects market sentiment and overall investor confidence. Monitoring these trends helps in understanding the stock's volatility and potential growth trajectory. As of April 18, 2025, AWH stock is trading at $2.64.

Aspira Women's Health Inc. does not currently offer a dividend yield, as the company has not declared any dividend payouts. Therefore, dividend payout ratios are not applicable.

Analyst consensus plays a significant role in shaping investor perceptions. Examining whether analysts recommend a buy, hold, or sell stance on Aspira Women's Health Inc. offers insights into professional evaluations of the stock's potential. The consensus is to buy the stock.

Here is a summary of key valuation metrics for Aspira Women's Health Inc. (AWH):

For more insights into the company's strategic direction, explore: Mission Statement, Vision, & Core Values of Aspira Women's Health Inc. (AWH).

Aspira Women's Health Inc. (AWH) Risk Factors

Understanding the risks that Aspira Women's Health Inc. (AWH) faces is crucial for investors. These risks can be both internal and external, significantly impacting the company’s financial health and future prospects.

Here's an overview of key risks:

• Industry Competition: The women's health diagnostics market is competitive. Aspira Women's Health Inc. (AWH) faces competition from established diagnostic companies, as well as emerging players with innovative technologies. Intense competition could lead to pricing pressures, reduced market share, and decreased profitability.
• Regulatory Changes: Changes in healthcare regulations and reimbursement policies can significantly affect Aspira Women's Health Inc. (AWH)'s revenue. Diagnostic tests are subject to stringent regulatory requirements, and changes in these regulations can increase compliance costs and delay the introduction of new products.
• Market Conditions: Economic downturns and changes in healthcare spending can impact the demand for diagnostic tests. A decrease in discretionary healthcare spending could reduce the volume of tests ordered, affecting Aspira Women's Health Inc. (AWH)'s financial performance.

Operational, financial, and strategic risks are often highlighted in Aspira Women's Health Inc. (AWH)'s earnings reports and filings. These include:

• Operational Risks: These risks involve the day-to-day challenges of running a business, such as maintaining the quality and reliability of diagnostic tests, managing supply chains, and ensuring efficient operations. Any disruption in these areas can lead to increased costs and decreased revenue.
• Financial Risks: Financial risks relate to the company's ability to manage its cash flow, debt, and capital structure. Aspira Women's Health Inc. (AWH) may face challenges in securing financing for research and development, marketing, and expansion. Fluctuations in interest rates and changes in credit markets can also impact the company's financial stability.
• Strategic Risks: Strategic risks involve the decisions and plans that guide the company's long-term direction. These risks include the ability to innovate and develop new products, adapt to changing market conditions, and execute strategic initiatives effectively. Failure to address these risks can lead to a loss of competitive advantage and decreased shareholder value.

Mitigation strategies and plans are crucial for addressing these risks. While specific details may vary, common strategies include:

• Diversification: Expanding the range of diagnostic tests and services can reduce the company's reliance on any single product or market.
• Cost Management: Implementing cost-saving measures and improving operational efficiency can enhance profitability and financial stability.
• Strategic Partnerships: Collaborating with other companies and organizations can provide access to new technologies, markets, and resources.
• Compliance Programs: Ensuring compliance with healthcare regulations and ethical standards can minimize the risk of legal and regulatory issues.

Understanding Aspira Women's Health Inc. (AWH)'s risk factors and mitigation strategies is essential for making informed investment decisions. By carefully assessing these factors, investors can better evaluate the company's potential and make sound choices.

For more insights into Aspira Women's Health Inc. (AWH)'s mission and vision, check out: Mission Statement, Vision, & Core Values of Aspira Women's Health Inc. (AWH).

Aspira Women's Health Inc. (AWH) Growth Opportunities

Aspira Women's Health Inc. (AWH) faces several potential growth drivers. These include innovative product development, strategic market expansion, potential acquisitions, and the establishment of key partnerships. The company's future success hinges on capitalizing on these opportunities.

Aspira Women's Health Inc. (AWH) focuses on strategic initiatives to enhance growth. These initiatives include:

• Expanding the reach of existing products.
• Developing and launching new diagnostic tools.
• Pursuing strategic collaborations to broaden market access.

Aspira Women's Health Inc. (AWH) operates in a competitive landscape, relying on several competitive advantages to secure its growth prospects:

• Proprietary Technology: Aspira Women's Health Inc. (AWH) leverages its exclusive technology to differentiate its diagnostic offerings.
• Established Market Presence: The company benefits from existing relationships with healthcare providers.
• Focus on Women's Health: Aspira Women's Health Inc. (AWH)'s specialization in women’s health provides a focused approach to address specific market needs.

To gain more insight into the investors and motivations behind Aspira Women's Health Inc. (AWH), explore this resource: Exploring Aspira Women's Health Inc. (AWH) Investor Profile: Who’s Buying and Why?